TG Therapeutics Inc Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Prakhar Agrawal - Cantor Fitzgerald - Analyst : Hi, good morning, and thank you for taking my questions and congrats on all the progress. So maybe firstly, you mentioned about January and February being a strong growth and 2025 guide to meaningfully exceed the $525 million that you gave. So maybe just give more color around that, what you're seeing? What are the biggest segments of growth as you look towards the rest of the year? And secondly, OCREVUS has a high-dose read out this year. Maybe if you can talk about where you see that product playing a role in the market, that would be super helpful. Thank you.

Question: Michael DiFiore - Evercore ISI - Analyst : Hey guys, thanks for taking my call and congrats on all the progress. Two for me. Obviously, it seems like the pivotal Phase 3 subcutaneous trial for BRIUMVI may come around the middle of the year. To the extent that you can, I mean, has the subcu trial design been finalized? And can you confirm whether Q2 months or Q3 months remains the target regimen? And finally, just a follow-up, the expectations on growth to net for the balance of the year. Thank you.

Question: Michael DiFiore - Evercore ISI - Analyst : Got it, thanks so much.

Question: Edward White - H.C. Wainwright & Co., LLC - Analyst : Great, thanks for taking my question. So just a follow-up question on the subcu potential. How are you thinking about the size of that trial and the timing for enrollment seeing is that it's a competitive market that's already penetrated.

Question: Edward White - H.C. Wainwright & Co., LLC - Analyst : Okay. Thanks. And then just I appreciate the OpEx guidance. How should we be thinking about that regarding SG&A versus R&D? The question on SG&A is just is the salesforce rightsized now or continue to add there? And are there any marketing schemes going forward that might lead to increased SG&A costs?

Question: Edward White - H.C. Wainwright & Co., LLC - Analyst : Okay, great. Thanks, Mike. Thanks for taking my questions.

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Hi, good morning. Thanks for taking the questions. Just on your feedback at ACTRIMS, I'm wondering what the reception has been like to the ENHANCE trial data to the extent docs are apt to modify use today based on the data that you're seeing so far? And how much more would a formal label expansion drive utilization based on the feedback you're getting so far? And then, I guess looking to that end, I guess, when all said and done, would you expect to file an sBLA for a consolidated certain enhanced infusion regimen?

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Okay, great. Maybe one follow-up, if I could. Just thinking about the myasthenia gravis expansion opportunity. I guess when you talk to neurologists, how are they thinking about sort of how broadly an anti-CD20 approach might be adopted, particularly in relation to the anti-C5 and [FCRM] blockers? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MARCH 03, 2025 / 1:30PM, TGTX.OQ - Q4 2024 TG Therapeutics Inc Earnings Call

Question: Eric Joseph - J.P. Morgan Securities LLC - Analyst : Great. Thanks for taking the questions.

Question: Mayank Mamtani - B. Riley Securities, Inc. - Analyst : Yes, good morning team. Thanks for taking our questions and congrats on a great start to 2025. Are you able to share the revenue split of new two BRIUMVI versus maintenance, patient segment? And just wondering, looking forward, has there been a change to an internal assumption when maintenance segment revenues exceed that of new patients? And just a two-part question here. On a dynamic market share basis, are you able to comment on what -- where you stand based on how you look at switch from another DMT or CD20 therapy?

Question: Mayank Mamtani - B. Riley Securities, Inc. - Analyst : Great. And just on the pipeline front, if you're able to give us some color on the size of the allergenic CD20 study that you're starting enrollment shortly here and kind of what would be the timelines and maybe study objectives? I understand this would be dose findings initially, but any pharmacodynamic data that we could expect would be helpful to get some color, Mike. Thanks for taking your question.

Question: Mayank Mamtani - B. Riley Securities, Inc. - Analyst : Great, very helpful. Thank you, Mike.